| Name | Title | Contact Details |
|---|
Empirico is a venture-backed, next-generation therapeutics company founded on utilizing huge biological data sets, human genetics and programmable biology to power novel target discovery and development.
Caladrius is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of cell therapies designed to reverse disease and/or promote the regeneration of damaged tissue. The Company is developing first-in-class therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the growth of new microvasculature. The Company`s platform technology leverages these cells to enable the body`s natural repair mechanisms using formulations unique to each medical indication.
Targacept`s clinical pipeline is built on a unique class of therapeutic targets.
480 Biomedical focuses on the development of a bioresorbable scaffold for treating occlusive disease in the superficial femoral artery.
BioMotiv is an accelerator company associated with The Harrington Project, a $340 million initiative centered at University Hospitals of Cleveland.